VP Regulatory Affairs
Richard Jiang, VP Regulatory Affairs
Richard Jiang is knowledgeable, technically skilled and strategically focused Regulatory affairs and drug development with 18+ years of solid China regulatory experience, four years working experience in the United States (focused on US, Japan, South Korea regulatory practice), four years global drug development experience. Richard Jiang worked in Bayer for 7 years, Led Regulatory Affairs team to achieve the approval of new drug Nexavar for Renal Cell Cancer in China by only 2 months after Europe EMEA, 9 months after USA FDA approval. This is still the fastest NDA approval of industry record in China. Richard also worked in Covance, Roche and GSK China for 7 years. Richard joined in GSK Oncology R&D Center, United State, in 2012, as Sr. Director, led NDA submission and approval in China/Japan/Korea. Richard got MBA from the University of Queensland, Australia, and as a Pharmacist graduated from Second Military Medical University, Shanghai, China.